Zimmer Biomet Holdings (ZBH) just reported a second-quarter update that caught investor attention. Revenue and earnings topped analyst expectations, full-year guidance was raised, and the Paragon 28 acquisition and US commercial changes featured prominently.

Zimmer Biomet Holdings' recent Q2 beat and higher guidance have come alongside a clear shift in market sentiment, with the share price at $97.19 and a 90 day share price return of 18.05%, even though the 5 year total shareholder return has declined 28.55%. The raised outlook, progress on the US sales force reshaping and an active buyback program appear to be reinforcing near term momentum, while the weaker 1 year total shareholder return of 0.22% decline highlights that longer term holders have yet to see a sustained recovery.

If Zimmer Biomet's use of robotics and AI in surgery has caught your eye, this is a good moment to branch out and see 42 healthcare AI stocks

Zimmer Biomet Holdings has put up better numbers and the stock has responded. The real test now is how much of this move reflects the business progress versus investors simply rethinking the story, which is where valuation comes in next.

Most Popular Narrative: 4.9% Undervalued

Zimmer Biomet Holdings is trading at $97.19 against a widely followed fair value narrative of $102.19, which points to a modest undervaluation and puts the focus squarely on whether the company can match those expectations.

The company's focused investment in digital health, robotics, and data-driven surgical solutions (including the ROSA and upcoming Monogram platforms) is increasing adoption of premium offerings, enabling margin expansion due to product mix and driving recurring revenues through connected care ecosystems, supporting higher net margins and earnings predictability.

Want to see what sits behind that fair value for Zimmer Biomet Holdings? The narrative focuses on steady revenue expansion, fatter margins, and a lower future earnings multiple that still supports today’s price. Curious which assumptions matter most and how much execution headroom is built in? The full story ties those moving parts together in detail.

Result: Fair Value of $102.19 (UNDERVALUED)

However, Zimmer Biomet Holdings still faces real tests, including tougher pricing and reimbursement conditions, as well as the risk that recent acquisitions take longer to integrate smoothly.

Next Steps

With sentiment on Zimmer Biomet Holdings looking mixed, this is a moment to check the facts yourself and form a clear opinion quickly. A balanced starting point is to weigh the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Zimmer Biomet Holdings?

Zimmer Biomet Holdings may be front of mind today, but you give yourself a better shot at strong outcomes by lining up a few more well researched ideas.

• Target dependable cash flow by reviewing companies in the 9 dividend fortresses that focus on income strength and resilience.
• Hunt for quality at a reasonable price by checking the 50 high quality undervalued stocks that blend solid fundamentals with appealing valuations.
• Prioritise capital protection first by scanning the 78 resilient stocks with low risk scores that score well on balance sheet strength and risk controls.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.